Metabolism-based artificial organelles: From precise construction to smart theranostics
Source abstract
Abstract
Cellular metabolic dysregulation is a core driver of major diseases, including cancer, neurodegenerative disorders, and cardiovascular conditions. However, conventional interventions such as small-molecule drugs and gene editing are hampered by off-target effects, delivery challenges, and a lack of spatiotemporal precision, resulting in a failure to effectively reengineer pathological metabolic networks. Artificial organelles, constructed via a "bottom-up" bioinspired approach, represent a paradigm shift from systemic intervention to "metabolic system reconstruction," offering a revolutionary strategy to precisely mimic, repair, or augment specific metabolic functions at the subcellular level. Here, we systematically review recent advances in metabolism-based artificial organelles, from their precise construction to smart theranostic applications. We first elaborate on the core construction strategies, including lipid and protein self-assembly, microfluidics, 3D bioprinting and biomembrane fusion for enabling dynamic interactions and content delivery, followed by a dissection of the design principles for modulating three metabolic pillars: (1) remodeling energy metabolism by mimicking mitochondrial function and regulating glycolysis; (2) controlling biosynthesis by emulating the endoplasmic reticulum (ER) and substance transport networks; and (3) reshaping redox homeostasis by mimicking peroxisomes through multienzyme cascades and intelligent responsive systems that precisely regulate signaling molecules such as reactive oxygen species (ROS). We link these functional designs to specific metabolic vulnerabilities in diseases and showcase applications in neurodegenerative disorders, cancer, cardiovascular diseases, and inflammatory conditions. Specific strategies include repairing damaged neurons through synergistic energy supplementation and antioxidation or inhibiting tumors via a combination of "starvation therapy" and pro-oxidative "gas therapy." Finally, we critically address the key challenges in biocompatibility, systemic complexity, in vivo delivery, and clinical translation and outline future perspectives toward intelligent, autonomous systems integrated with artificial intelligence (AI)-driven design and multiscale, "artificial tissue" constructs. This review aims to provide a theoretical framework and technological roadmap for designing the next generation of smart metabolic intervention tools. Scheme. Artificial organelles (AOs) represent a paradigm shift from systemic intervention to 'metabolic system reconstruction' for treating diseases driven by metabolic dysregulation. This review presents a comprehensive framework spanning bottom-up construction strategies (self-assembly to 3D bioprinting), functional designs targeting three metabolic pillars (energy metabolism, biosynthesis, redox homeostasis), and precision therapeutic applications in cancer, neurodegeneration, and inflammatory diseases. We critically analyze translational challenges including biocompatibility, scalability, and in vivo delivery, while proposing future directions toward AI-driven intelligent systems. This work provides a roadmap for engineering next-generation metabolic intervention tools.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Supramolecular Self-Assembly in Materials · Cancer, Hypoxia, and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Surface molecularly engineered Mitochondria conduct immunophenotype repolarization of tumor-associated macrophages to potentiate cancer immunotherapy
2. Evolving emulsion microcompartments via enzyme-mimicking amyloid-mediated interfacial catalysis10.1002/smll.202409601 ↗
3. Nanoarchitectonics with a membrane-embedded electron shuttle mimics the bioenergy anabolism of mitochondria10.1002/anie.202319116 ↗
4. Advances in giant unilamellar vesicle preparation techniques and applications10.1016/j.cis.2023.102935 ↗
5. Recent progress in micro/nanoreactors toward the creation of artificial organelles10.1002/adhm.201700917 ↗
6. Artificial organelles: towards adding or restoring intracellular activity10.1002/cbic.202000850 ↗
7. Advancing the design of artificial nano-organelles for targeted cellular detoxification of reactive oxygen species10.1021/acs.nanolett.3c03888 ↗
8. Exploring nanozymes for organic substrates: building nano-organelles10.1002/anie.202408277 ↗
9. Transformative impact of nanocarrier-mediated drug delivery: overcoming biological barriers and expanding therapeutic Horizons10.1002/smsc.202400280 ↗
10. Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release10.1016/j.addr.2024.115239 ↗
11. Biomimetic materials to fabricate artificial cells10.1021/acs.chemrev.4c00241 ↗
12. A systematic review of nanocarriers used in medicine and beyond - definition and categorization framework10.1186/s12951-025-03113-7 ↗
13. Biomimetic artificial organelles with in vitro and in vivo activity triggered by reduction in microenvironment10.1038/s41467-018-03560-x ↗
14. Cascade reactions in multicompartmentalized polymersomes10.1002/anie.201308141 ↗
15. Microfluidic assembly of monodisperse vesosomes as artificial cell models10.1021/jacs.6b10977 ↗
16. Microfluidic formation of monodisperse coacervate organelles in liposomes10.1002/anie.201703145 ↗
17. Light-triggered enzymatic reactions in nested vesicle reactors10.1038/s41467-018-03491-7 ↗
18. Dynamic synthetic cells based on liquid-liquid phase separation10.1002/cbic.201900183 ↗
19. Nanozyme-based artificial organelles: an emerging direction for artificial organelles10.1002/smll.202202294 ↗
20. Artificial compartments encapsulating enzymatic reactions: towards the construction of artificial organelles
21. Self-organizing microdroplet protocells displaying light-driven oscillatory and morphological evolution
22. Nanozyme-powered giant unilamellar vesicles for mimicry and modulation of intracellular oxidative stress10.1021/acsami.1c05512 ↗
23. An active tethering mechanism controls the fate of vesicles10.1038/s41467-021-25465-y ↗
24. A versatile magnetic nanoplatform for plug-and-play functionalization: genetically programmable cargo loading to bacterial magnetosomes by SpyCatcher “Click Biology”10.1021/acsnano.4c05588 ↗
25. Tailoring of peptide vesicles: a Bottom-Up chemical approach10.1021/acs.accounts.0c00690 ↗
26. Ionic combisomes: a new class of biomimetic vesicles to fuse with life
27. Spatiotemporal dynamic assembly/disassembly of organelle-mimics based on intrinsically disordered protein-polymer conjugates
28. Synthetic-cell-based multi-compartmentalized hierarchical systems
29. Dynamic self-assembly of compartmentalized DNA nanotubes10.1038/s41467-021-23850-1 ↗
30. Spontaneous curvature induction in an artificial bilayer membrane10.1002/anie.202403900 ↗
31. A cellular platform for the development of synthetic living machines10.1126/scirobotics.abf1571 ↗
32. Self-assembly of “patchy” nanoparticles: a versatile approach to functional hierarchical materials10.1039/C5SC01141H ↗
33. Self-assembled polymeric vesicles: focus on polymersomes in cancer treatment10.1016/j.jconrel.2020.12.027 ↗
34. Protein assembly: versatile approaches to construct highly ordered nanostructures10.1021/acs.chemrev.6b00228 ↗
35. Self-assembly of polymers and their applications in the fields of biomedicine and materials10.3390/polym16152097 ↗
36. Self-assembly of organelle-localized neuropeptides triggers intrinsic apoptosis against breast cancer10.1002/adhm.202300265 ↗
37. A dynamic control center based on a DNA reaction network for programmable building of DNA nanostructures10.1021/acsnano.2c12360 ↗
38. Pushing the boundary of cancer diagnostics through microfluidic technologies
39. Paper based microfluidic devices: a review of fabrication techniques and applications10.1140/epjs/s11734-022-00727-y ↗
40. Spatiotemporal control of signal-driven enzymatic reaction in artificial cell-like polymersomes10.1038/s41467-022-32889-7 ↗
41. Bottom-up assembly of target-specific cytotoxic synthetic cells10.1016/j.biomaterials.2022.121522 ↗
42. Two-photon 3D laser printing inside synthetic cells10.1002/adma.202106709 ↗
43. Exploring living multicellular organisms, organs, and tissues using microfluidic systems10.1021/cr200432q ↗
44. Advanced Bottom-Up engineering of living architectures10.1002/adma.201903975 ↗
45. Recent advances in 3D printing sacrificial templates for fabricating engineered vasculature
46. Embedding carbon nanotubes in artificial cells enhances probe transfer
47. Light-activated communication in synthetic tissues10.1126/sciadv.1600056 ↗
48. A tissue-like printed material10.1126/science.1229495 ↗
49. Interface engineering in multiphase systems toward synthetic cells and organelles: from soft matter fundamentals to biomedical applications10.1002/adma.202002932 ↗
50. Advances in microfluidic technologies in organoid research10.1002/adhm.202302686 ↗
51. Artificial mitochondrial nanorobots deliver energy in vivo by oral administration10.1002/adma.202500495 ↗
52. Mitochondria transfer enhances proliferation, migration, and osteogenic differentiation of bone marrow mesenchymal stem cell and promotes bone defect healing10.1186/s13287-020-01704-9 ↗
53. Cell-penetrating artificial mitochondria-targeting peptide-conjugated metallothionein 1A alleviates mitochondrial damage in Parkinson’s disease models10.1038/s12276-018-0124-z ↗
54. Nanoparticle-based artificial mitochondrial DNA transcription regulator: mitoscript10.1021/acs.nanolett.2c03958 ↗
55. Identification, characteristics and function of phosphoglucomutase (PGM) in the agar biosynthesis and carbon flux in the agarophyte Gracilariopsis lemaneiformis (Rhodophyta)10.3390/md20070442 ↗
56. Protocell flow reactors for enzyme and whole-cell mediated biocatalysis10.1002/adma.202404607 ↗
57. X-ray reflectivity study of the heat shock protein Hsp70 interaction with an artificial cell membrane model10.1038/s41598-023-46066-3 ↗
58. Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis10.1038/onc.2008.308 ↗
59. Dialogue between mitochondria and endoplasmic reticulum-potential therapeutic targets for age-related cardiovascular diseases
60. The role of endoplasmic reticulum-mitochondria contact sites in the control of glucose homeostasis: an update10.1038/s41419-018-0416-1 ↗
61. Broadening horizons: the contribution of mitochondria-associated endoplasmic reticulum membrane (MAM) dysfunction in diabetic kidney disease10.7150/ijbs.86608 ↗
62. Emerging functions of the mitochondria-ER-lipid droplet three-way junction in coordinating lipid transfer, metabolism, and storage in cells10.1002/1873-3468.14893 ↗
63. The ER-mitochondria interface, where Ca(2+) and cell death meet10.1016/j.ceca.2023.102743 ↗
64. Structural and functional features and significance of the physical linkage between ER and mitochondria10.1083/jcb.200604016 ↗
65. Engineering cell membrane-cloaked catalysts as multifaceted artificial peroxisomes for biomedical applications
66. Targeting NRF2 and its downstream processes: opportunities and challenges10.1146/annurev-pharmtox-052220-104025 ↗
67. External triggering and triggered targeting strategies for drug delivery10.1038/natrevmats.2017.20 ↗
68. Mitochondrial dysfunction in neurodegenerative disorders: potential therapeutic application of mitochondrial transfer to central nervous system-residing cells10.1186/s12967-023-04493-w ↗
69. Mitochondrial dysfunction in neurodegenerative disorders10.1016/j.neurot.2023.10.002 ↗
70. Oxidative stress, mitochondrial damage and neurodegenerative diseases
71. Overcoming mitochondrial dysfunction in neurodegenerative diseases10.4103/1673-5374.360279 ↗
72. Human neural stem cell-derived artificial organelles to improve oxidative phosphorylation10.1038/s41467-024-52171-2 ↗
73. Mitochondria-targeting ceria nanoparticles as antioxidants for Alzheimer’s disease10.1021/acsnano.5b08045 ↗
74. Advanced biological applications of cerium oxide nanozymes in disease related to oxidative damage10.1021/acsomega.3c03661 ↗
75. Intranasal liposomes co-delivery of Aβ-targeted KLVFF and ROS-responsive ceria for synergistic therapy of Alzheimer’s disease10.1016/j.cej.2024.153210 ↗
76. Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases10.1016/j.jconrel.2016.05.044 ↗
77. Brain delivery of nanomedicines: Trojan horse liposomes for plasmid DNA gene therapy of the brain10.3389/fmedt.2020.602236 ↗
78. Silica-coated magnetic nanoparticles activate microglia and induce neurotoxic d-serine secretion10.1186/s12989-021-00420-3 ↗
79. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate10.1016/j.ccr.2012.02.014 ↗
80. Nanomedicines targeting metabolism in the tumor microenvironment10.3389/fbioe.2022.943906 ↗
81. Glucose oxidase-loaded MnFe2O4 nanoparticles for hyperthermia and cancer starvation therapy10.1021/acsanm.2c04960 ↗
82. Rational design of non-toxic GOx-based biocatalytic nanoreactor for multimodal synergistic therapy and tumor metastasis suppression10.7150/thno.65399 ↗
83. Hypoxia signaling in cancer: implications for therapeutic interventions10.1002/mco2.203 ↗
84. Cancer metabolism: the role of ROS in DNA damage and induction of apoptosis in cancer cells10.3390/metabo13070796 ↗
85. Enzyme-integrated hydrogels for advanced biological applications10.1021/polymscitech.5c00076 ↗
86. Indole-3-acetic acids and horseradish peroxidase: a new prodrug/enzyme combination for targeted cancer therapy10.2174/1381612023394610 ↗
87. Improving cancer immunotherapy: exploring and targeting metabolism in hypoxia microenvironment
88. Hypoxia-driven immunosuppressive metabolites in the tumor microenvironment: new approaches for combinational immunotherapy10.3389/fimmu.2018.01591 ↗
89. Tumor integrin-targeted glucose oxidase enzyme promotes ROS-mediated cell death that combines with interferon alpha therapy for tumor control10.1158/1535-7163.MCT-24-0163 ↗
90. Recent advances in glucose oxidase-based nanocarriers for tumor targeting therapy
91. Biomimetic nanoparticles to enhance the reverse cholesterol transport for selectively inhibiting development into foam cell in atherosclerosis10.1186/s12951-023-02040-9 ↗
92. Rationally designed bioactive milk-derived protein scaffolds enhanced new bone formation
93. Autophagy: a double-edged sword in ischemia-reperfusion injury10.1186/s11658-025-00713-x ↗
94. Protective effects of Pt-N-C single-atom nanozymes against myocardial ischemia-reperfusion injury10.1038/s41467-024-45927-3 ↗
95. Mitochondria-targeted ROS scavenger JP4-039 improves cardiac function in a post-myocardial infarction animal model and induces angiogenesis in vitro10.1371/journal.pone.0320703 ↗
96. Targeting mitochondrial reactive oxygen species: JP4-039’s potential as a cardiovascular therapeutic10.3390/jcm14186465 ↗
97. Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms10.3389/fbioe.2023.1205751 ↗
98. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury10.1681/ASN.2010080808 ↗
99. Review: synovial cell metabolism and chronic inflammation in rheumatoid arthritis10.1002/art.40504 ↗
100. Synovial macrophages in rheumatoid arthritis: the past, present, and future10.1155/2020/1583647 ↗